NEW YORK, May 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (NASDAQ:INSY) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased INSYS securities between February 23, 2016 and March 15, 2017, both dates inclusive (the "Class Period"). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/insy.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) as a result, INSYS lacked effective internal controls over financial reporting; and (4) consequently, the Company’s public statements were materially false and misleading at all relevant times.
On March 15, 2017, after-market hours, INSYS announced that it postponed filing its financial results for the quarter and year ended December 31, 2016. INSYS told investors that “[t]he Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016.” Following this news, INSYS stock dropped $0.49 per share, or 4.64%, to close at $10.06 on March 16, 2017.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/insy or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 



